Pharmacodynamic Model-Based Safety Management of Eribulin-Induced Myelosuppression in Patients With Breast Cancer.

Kasai, Hidefumi; Poppenberg, Kim Linda; Fermanelli, Valentina; Otani, Yuki; Tanigawara, Yusuke

Kasai, Hidefumi; Poppenberg, Kim Linda; Fermanelli, Valentina; Otani, Yuki; Tanigawara, Yusuke.

Afiliación

Kasai H; Laboratory of Pharmacometrics and Systems Pharmacology, Keio Frontier Research and Education Collaboration Square (K-FRECS) at Tonomachi, Keio University, Kawasaki, Kanagawa, Japan.
Poppenberg KL; Keio University School of Medicine, Tokyo, Japan.
Fermanelli V; Keio University School of Medicine, Tokyo, Japan.
Otani Y; Sonnen Apotheke, Borkener Straße Dorsten, Germany; and.
Tanigawara Y; Keio University School of Medicine, Tokyo, Japan.

Ther Drug Monit ; 45(3): 318-326, 2023 06 01.

Article en En | MEDLINE | ID: mdl-36150714

Asunto(s)

Neoplasias de la Mama; Neutropenia; Humanos; Femenino; Neoplasias de la Mama/tratamiento farmacológico; Teorema de Bayes; Cetonas/efectos adversos; Neutropenia/inducido químicamente

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias de la Mama / Neutropenia Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Ther Drug Monit Año: 2023 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google